Lexaria Historical Income Statement

LEXXW Stock

USD 0.75 0.04 5.63%

Historical analysis of Lexaria Bioscience income statement accounts such as Total Operating Expenses of 6.5 M can show how well Lexaria Bioscience Corp performed in making a profits. Evaluating Lexaria Bioscience income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lexaria Bioscience's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lexaria Bioscience Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lexaria Bioscience Corp is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Lexaria Income Statement Analysis

Lexaria Bioscience Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lexaria Bioscience shareholders. The income statement also shows Lexaria investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Lexaria Bioscience Income Statement Chart

At this time, Lexaria Bioscience's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 125.2 K in 2024, despite the fact that Operating Income is likely to grow to (5.5 M).

Other Operating Expenses Operating Income Total Operating Expenses Net Income Income Tax Expense Total Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lexaria Bioscience Corp. It is also known as Lexaria Bioscience overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Lexaria Bioscience Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lexaria Bioscience Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Lexaria Bioscience Corp financial statement analysis. It represents the amount of money remaining after all of Lexaria Bioscience Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Total Revenue

Total revenue comprises all receipts Lexaria Bioscience Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Lexaria Bioscience's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2021	2023	2024 (projected)
Other Operating Expenses	7.6M	6.2M	3.2M
Interest Expense	114.3K	102.9K	125.2K

Other Operating Expenses Interest Expense

Lexaria Bioscience income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Selling General Administrative	Selling And Marketing Expenses	Research Development	Net Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Minority Interest
Depreciation And Amortization		0.68	-0.01	0.1	0.11	0.15	-0.06	0.16	-0.04	0.16	0.17	0.69	0.57	0.56	-0.19	-0.44	0.12	0.08	0.0	0.15	0.13
Interest Expense	0.68		-0.17	0.29	0.29	0.32	-0.23	0.2	0.03	0.22	0.04	0.9	0.57	0.86	-0.25	-0.63	0.01	0.0	0.14	0.07	0.12
Other Operating Expenses	-0.01	-0.17		-0.95	-0.95	-0.94	0.94	-0.92	0.07	-0.88	-0.29	-0.16	0.38	-0.48	0.93	0.59	0.73	0.43	-0.89	0.77	0.58
Operating Income	0.1	0.29	-0.95		1.0	1.0	-1.0	0.97	-0.04	0.93	0.23	0.31	-0.32	0.63	-0.89	-0.6	-0.73	-0.57	0.95	-0.78	-0.61
Ebit	0.11	0.29	-0.95	1.0		1.0	-1.0	0.96	-0.07	0.92	0.24	0.31	-0.34	0.64	-0.89	-0.61	-0.73	-0.59	0.94	-0.79	-0.62
Ebitda	0.15	0.32	-0.94	1.0	1.0		-0.99	0.96	-0.07	0.93	0.24	0.34	-0.31	0.67	-0.89	-0.63	-0.72	-0.59	0.94	-0.78	-0.61
Total Operating Expenses	-0.06	-0.23	0.94	-1.0	-1.0	-0.99		-0.96	0.06	-0.93	-0.23	-0.25	0.39	-0.6	0.88	0.58	0.72	0.6	-0.95	0.79	0.63
Income Before Tax	0.16	0.2	-0.92	0.97	0.96	0.96	-0.96		0.11	0.99	0.1	0.26	-0.31	0.55	-0.87	-0.58	-0.74	-0.6	0.97	-0.75	-0.53
Total Other Income Expense Net	-0.04	0.03	0.07	-0.04	-0.07	-0.07	0.06	0.11		0.25	-0.85	0.18	0.34	0.02	0.13	-0.01	-0.03	-0.05	0.15	0.15	0.32
Net Income	0.16	0.22	-0.88	0.93	0.92	0.93	-0.93	0.99	0.25		-0.06	0.28	-0.26	0.55	-0.81	-0.58	-0.73	-0.62	0.97	-0.69	-0.44
Income Tax Expense	0.17	0.04	-0.29	0.23	0.24	0.24	-0.23	0.1	-0.85	-0.06		-0.03	-0.21	0.12	-0.4	-0.09	-0.04	0.19	0.0	-0.31	-0.54
Total Revenue	0.69	0.9	-0.16	0.31	0.31	0.34	-0.25	0.26	0.18	0.28	-0.03		0.72	0.9	-0.19	-0.49	-0.14	-0.12	0.19	-0.11	-0.04
Gross Profit	0.57	0.57	0.38	-0.32	-0.34	-0.31	0.39	-0.31	0.34	-0.26	-0.21	0.72		0.34	0.34	-0.04	0.24	0.36	-0.37	0.38	0.39
Cost Of Revenue	0.56	0.86	-0.48	0.63	0.64	0.67	-0.6	0.55	0.02	0.55	0.12	0.9	0.34		-0.5	-0.66	-0.35	-0.36	0.5	-0.41	-0.31
Selling General Administrative	-0.19	-0.25	0.93	-0.89	-0.89	-0.89	0.88	-0.87	0.13	-0.81	-0.4	-0.19	0.34	-0.5		0.62	0.48	0.23	-0.82	0.63	0.6
Selling And Marketing Expenses	-0.44	-0.63	0.59	-0.6	-0.61	-0.63	0.58	-0.58	-0.01	-0.58	-0.09	-0.49	-0.04	-0.66	0.62		0.15	0.09	-0.47	0.18	0.15
Research Development	0.12	0.01	0.73	-0.73	-0.73	-0.72	0.72	-0.74	-0.03	-0.73	-0.04	-0.14	0.24	-0.35	0.48	0.15		0.77	-0.77	0.82	0.37
Net Interest Income	0.08	0.0	0.43	-0.57	-0.59	-0.59	0.6	-0.6	-0.05	-0.62	0.19	-0.12	0.36	-0.36	0.23	0.09	0.77		-0.66	0.65	0.26
Net Income From Continuing Ops	0.0	0.14	-0.89	0.95	0.94	0.94	-0.95	0.97	0.15	0.97	0.0	0.19	-0.37	0.5	-0.82	-0.47	-0.77	-0.66		-0.74	-0.51
Reconciled Depreciation	0.15	0.07	0.77	-0.78	-0.79	-0.78	0.79	-0.75	0.15	-0.69	-0.31	-0.11	0.38	-0.41	0.63	0.18	0.82	0.65	-0.74		0.79
Minority Interest	0.13	0.12	0.58	-0.61	-0.62	-0.61	0.63	-0.53	0.32	-0.44	-0.54	-0.04	0.39	-0.31	0.6	0.15	0.37	0.26	-0.51	0.79

Click cells to compare fundamentals

Lexaria Bioscience Account Relationship Matchups

Lexaria Bioscience income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	146.1K	147.6K	146.9K	145.4K	130.9K	132.7K
Interest Expense	59.0K	150.6K	137.1K	114.3K	102.9K	125.2K
Other Operating Expenses	4.4M	6.4M	7.6M	6.8M	6.2M	3.2M
Operating Income	(3.9M)	(5.7M)	(7.4M)	(6.5M)	(5.8M)	(5.5M)
Ebit	(4.1M)	(5.7M)	(6.7M)	(6.5M)	(5.9M)	(5.6M)
Ebitda	(4.0M)	(5.6M)	(6.5M)	(6.4M)	(5.8M)	(5.5M)
Total Operating Expenses	4.3M	6.2M	7.6M	6.7M	6.2M	6.5M
Income Before Tax	(4.1M)	(4.2M)	(7.4M)	(6.7M)	(5.8M)	(5.5M)
Total Other Income Expense Net	(192.7K)	1.5M	(764.6K)	(178.5K)	(42.2K)	(44.3K)
Net Income	(4.0M)	(2.5M)	(7.3M)	(6.7M)	(5.8M)	(5.5M)
Income Tax Expense	(54.3K)	(1.7M)	(114.3K)	130.9K	117.8K	123.7K
Total Revenue	384.5K	722.7K	255.4K	226.2K	464.3K	398.9K
Gross Profit	285.2K	547.4K	183.6K	194.7K	459.5K	482.4K
Cost Of Revenue	99.4K	175.3K	71.8K	31.5K	4.8K	4.6K
Selling General Administrative	3.6M	5.0M	5.7M	3.1M	3.9M	2.5M
Research Development	387.1K	1.3M	1.8M	3.7M	2.4M	1.2M
Net Income From Continuing Ops	(4.1M)	(4.2M)	(7.4M)	(6.7M)	(6.0M)	(6.3M)
Reconciled Depreciation	112.8K	147.6K	141.3K	145.4K	167.2K	96.1K
Minority Interest	150.6K	159.1K	114.3K	47.6K	54.8K	99.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexaria Historical Income Statement

About Lexaria Income Statement Analysis

Lexaria Bioscience Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Net Income

Total Revenue

Lexaria Bioscience income statement Correlations

Lexaria Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lexaria Bioscience income statement Accounts

Also Currently Popular

Additional Tools for Lexaria Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 0.99	Income Before Tax
Income Before Tax	+ 0.97	Operating Income
Net Income From Continuing Ops	+ 0.97	Income Before Tax

Total Operating Expenses	- 1.0	Ebit
Total Operating Expenses	- 1.0	Operating Income
Total Operating Expenses	- 0.99	Ebitda
Income Before Tax	- 0.96	Total Operating Expenses
Net Income From Continuing Ops	- 0.95	Total Operating Expenses
Ebit	- 0.95	Other Operating Expenses